clinical trial · NCT06520826
Vafseo Outcomes In-Center Experience
USRC Kidney Research·phase3·active not recruiting·n = 2,200
Anemia of Chronic Kidney DiseaseVadadustatErythropoiesis Stimulating Agent
brief summary
This trial is an investigator-initiated, multi-center, randomized (1:1), open-label, active-controlled, pragmatic study of the safety of vadadustat administered three times per week for the treatment of anemia in in-center hemodialysis patients with End Stage Kidney Disease (ESKD). This study will obtain long-term safety data in a large sample of subjects receiving in-center hemodialysis to support adoption of three times per week vadadustat dosing.
started
Nov 20, 2024
primary completion
Jun 30, 2026
completion
Jun 30, 2026
last updated
Mar 10, 2026
official title
Safety of Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Hemodialysis Subjects: Vafseo Outcomes In-Center Experience
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol